Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : NVSEF crawled date : 2022 - 03 - 25 save search
Worldwide Malaria Diagnostics Industry to 2026 - Featuring Access Bio, Novartis and Olympus Among Others
Published: 2022-03-25 (Crawled : 21:00) - prnewswire.com
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
| Email alert
Add to watchlist
NVSEF | $93.6375 6.88% 82K
|
Health Technology
| Email alert
Add to watchlist
NINOF | $10.2 -14.1% 260
|
Consumer Durables
| Email alert
Add to watchlist
TMO | $557.87 -1.3% 0.0% 1M
|
Health Technology
| Email alert
Add to watchlist
DHR | $239.66 -0.12% 0.0% 2.7M
|
Health Technology
| Email alert
Add to watchlist
NINOY | $10.185 -3.3% 5.7K
|
Manufacturing
| Email alert
Add to watchlist
ABT | $108.89 -0.2% 0.04% 4.6M
|
Health Technology
| Email alert
Add to watchlist
novartis diagnostics diagnostic malaria
Drugs for Immunotherapy Global Market Report 2022
Published: 2022-03-25 (Crawled : 18:00) - prnewswire.com
AZNCF | $138.88 -4.19% 960
|
Health Technology
|
| O: -6.55%
H: 7.81%
C: 7.56%
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
JNJ | $147.59 0.05% 0.0% 8.5M
|
Health Technology
|
| O: 0.65%
H: 0.0%
C: 0.0%
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: 0.28%
H: 1.09%
C: 0.18%
AZN | $68.75 -0.26% -0.26% 7.6M
|
Health Technology
|
| O: -1.58%
H: 1.16%
C: 0.23%
immunotherapy report market drug
Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi®) for the Treatment of Acute and Chronic Graft-Versus-Host Disease
Published: 2022-03-25 (Crawled : 14:00) - biospace.com/
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
INCY | $53.42 -0.8% -0.8% 1.6M
|
Health Technology
|
| O: 0.33%
H: 0.29%
C: 0.01%
jakavi treatment disease positive chmp
Cellular Immunotherapy Global Market Report 2022
Published: 2022-03-25 (Crawled : 14:00) - prnewswire.com
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
immunotherapy report market
Novartis receives positive CHMP opinion for Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma in Europe
Published: 2022-03-25 (Crawled : 12:20) - globenewswire.com
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
kymriah novartis europe car-t positive therapy chmp t-cell
Novartis receives positive CHMP opinion for Jakavi® to treat acute and chronic graft-versus-host disease
Published: 2022-03-25 (Crawled : 12:20) - globenewswire.com
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
jakavi novartis disease positive chmp
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.